CA2174552A1 - Derives de flavine utilises comme agents antiviraux - Google Patents

Derives de flavine utilises comme agents antiviraux

Info

Publication number
CA2174552A1
CA2174552A1 CA002174552A CA2174552A CA2174552A1 CA 2174552 A1 CA2174552 A1 CA 2174552A1 CA 002174552 A CA002174552 A CA 002174552A CA 2174552 A CA2174552 A CA 2174552A CA 2174552 A1 CA2174552 A1 CA 2174552A1
Authority
CA
Canada
Prior art keywords
flavin
derivative
treatment
infection
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002174552A
Other languages
English (en)
Inventor
Odur Ayuko Washington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RADOPATH Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2174552A1 publication Critical patent/CA2174552A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

On administre, à des mammifères, divers dérivés de flavine qui servent d'agents antiviraux. La riboflavine et des dérivés de riboflavine sont donnés comme des exemples spécifiques qui peuvent être préférés.
CA002174552A 1993-10-19 1994-10-19 Derives de flavine utilises comme agents antiviraux Abandoned CA2174552A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents
GB9321558.0 1993-10-19

Publications (1)

Publication Number Publication Date
CA2174552A1 true CA2174552A1 (fr) 1995-04-27

Family

ID=10743784

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2123825A Pending CA2123825A1 (fr) 1993-10-19 1994-05-18 Agents antiviraux
CA002174552A Abandoned CA2174552A1 (fr) 1993-10-19 1994-10-19 Derives de flavine utilises comme agents antiviraux

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2123825A Pending CA2123825A1 (fr) 1993-10-19 1994-05-18 Agents antiviraux

Country Status (26)

Country Link
EP (1) EP0739208A1 (fr)
JP (1) JPH09505804A (fr)
CN (1) CN1140992A (fr)
AP (1) AP620A (fr)
AU (1) AU7943794A (fr)
BG (1) BG100599A (fr)
BR (1) BR9407862A (fr)
CA (2) CA2123825A1 (fr)
CO (1) CO4520283A1 (fr)
CZ (1) CZ113796A3 (fr)
EE (1) EE9600057A (fr)
GB (2) GB9321558D0 (fr)
HR (1) HRP940688A2 (fr)
HU (1) HUT76322A (fr)
IL (1) IL111338A0 (fr)
JO (1) JO1866B1 (fr)
MA (1) MA23356A1 (fr)
MD (1) MD960168A (fr)
NO (1) NO961547L (fr)
OA (1) OA10579A (fr)
PE (1) PE5596A1 (fr)
PL (1) PL314008A1 (fr)
SK (1) SK50696A3 (fr)
UY (1) UY23844A1 (fr)
WO (1) WO1995011028A1 (fr)
ZA (1) ZA948191B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
EP1531823A4 (fr) * 2002-05-10 2007-07-18 Univ Ohio State Flavine n-oxydes: agents anti-cancer et agents d'eradication de pathogenes
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
CN100413866C (zh) * 2002-08-02 2008-08-27 中国人民解放军军事医学科学院放射医学研究所 核黄素衍生物及其制备方法与应用
EP2545788A1 (fr) * 2011-07-13 2013-01-16 Martin Hulliger Système diététique à plusieurs composants
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
CA3079952A1 (fr) * 2017-10-24 2019-05-02 Lunella Biotech, Inc. Mitoflavoscines : ciblage d'enzymes contenant de la flavine eliminant les cellules souches cancereuses (csc) par inhibition de la respiration mitochondriale
BR112022000175A2 (pt) * 2019-07-09 2022-02-22 Dsm Ip Assets Bv Reduzindo a atividade viral de elafibranor com riboflavina ou dha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (fr) * 1989-08-14 1991-03-07 John Bennett Kizer Produit et methode pour tuer les cellules anormales chez les vertebres
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (fr) * 1991-11-25 1993-06-10 University Of Michigan Composition et procede therapeutiques de prevention de lesions occasionnees par perfusion
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
AP9400695A0 (en) 1995-01-31
BR9407862A (pt) 1997-05-20
NO961547D0 (no) 1996-04-18
CZ113796A3 (en) 1996-11-13
JO1866B1 (en) 1995-12-27
GB2283913A (en) 1995-05-24
PE5596A1 (es) 1996-04-18
EE9600057A (et) 1996-10-15
SK50696A3 (en) 1997-01-08
PL314008A1 (en) 1996-08-05
CN1140992A (zh) 1997-01-22
WO1995011028A1 (fr) 1995-04-27
NO961547L (no) 1996-06-19
MA23356A1 (fr) 1995-07-01
UY23844A1 (es) 1995-03-28
AU7943794A (en) 1995-05-08
CA2123825A1 (fr) 1995-04-20
GB9421099D0 (en) 1994-12-07
OA10579A (en) 2002-06-19
CO4520283A1 (es) 1997-10-15
HUT76322A (en) 1997-08-28
BG100599A (en) 1997-02-28
MD960168A (ro) 1998-04-30
ZA948191B (en) 1995-06-08
HRP940688A2 (en) 1997-04-30
GB9321558D0 (en) 1993-12-08
HU9601006D0 (en) 1996-06-28
JPH09505804A (ja) 1997-06-10
AP620A (en) 1997-10-14
EP0739208A1 (fr) 1996-10-30
IL111338A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
Boretti et al. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome
DK175582B1 (da) Anvendelse af en 17-ketosteroid forbindelse til brug ved profylakse og behandling af retroviral infektion
CZ336899A3 (cs) Antimikrobiální prevence a léčba lidského viru imunodeficience a dalších infekčních onemocnění
JP5469706B2 (ja) 新規な葉酸代謝拮抗薬の組み合わせ療法
AU7402998A (en) Hiv and cancer treatment
KR20120101153A (ko) 점막염 및 체중 감소의 예방 및 치료를 위한 조성물 및 방법
Balzarini et al. Anti‐retrovirus activity of 9‐(2‐phosphonylmethoxyethyl) adenine (PMEA) in vivo increases when it is less frequently administered
WO1997004761A1 (fr) Procede et compositions pour traiter des proliferations anormales de cellules
CA2174552A1 (fr) Derives de flavine utilises comme agents antiviraux
US4910224A (en) Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
PL212010B1 (pl) Zastosowanie diacereiny lub jej farmaceutycznie dopuszczalnej pochodnej
WO2001006990A2 (fr) Utilisation d'etodolac pour traiter le cancer
Cartwright et al. Experimental production of a nutritional macrocytic anemia in swine
JPH06506212A (ja) Ｈｉｖウイルス系疾病、ヘルペス、色素性網膜炎およびマラリアの治療向けリボフラビンの利用
NL194430C (nl) Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
US5519028A (en) Antiviral preparations
EP0183352A2 (fr) Utilisation de suramine pour clinothérapie des infections par quelques-uns des membres de la famille des virus humains leucémiques de cellules-T (HTLV) y compris le virus lymphadénopathique (LAV)
Balzarini et al. Potentiating effect of ribavirin on the anti-retrovirus activity of 3′-azido-2, 6-diaminopurine-2′, 3′-dideoxyriboside in vitro and in vivo
EP0476391B1 (fr) Composition anti-SIDA contenant cépharanthine comme agent thérapeutique
GB2319474A (en) Anti-viral agents
Perno et al. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl) adenine to primary macrophages: efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus
RU2531945C2 (ru) Средство против передачи вич/спид половым путем
KR20150011386A (ko) 게르마늄의 착체 화합물, 이를 제조하는 방법, 및 약물
JP2000505433A (ja) レトロウイルス感染の処置のための３―アミノ―４―ヒドロキシ安息香酸の使用
JP2990015B2 (ja) 抗ｈｉｖ剤

Legal Events

Date Code Title Description
FZDE Discontinued